Trials / Terminated
TerminatedNCT03119701
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA
A Randomised, Parallel Group 2:1 Comparison of the Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) and Placebo in the Prevention of Multi-Organ Failure on Patients Surviving Open Surgery for a Ruptured Abdominal Aortic Aneurysm
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Faron Pharmaceuticals Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to assess effectiveness and safety of a drug FP-1201-lyo (Recombinant Human Interferon Beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery for a Ruptured Abdominal Aortic Aneurysm
Detailed description
This trial is multicentre, randomised, double-blinded, Phase II, parallel group comparison study of the efficacy and safety of FP-1201-lyo compared to placebo in patients surviving emergency open surgery for an infra-renal ruptured abdominal aortic aneurysm. Investigational medicinal product will be administered as post-surgical preventive treatment either 10µg FP-1201-lyo or placebo. Treatment will be administered daily every 24 hrs for 6 days. The first dose will be given after successful surgery at the point when the patient arrives to the Intensive Care Unit (ICU). Both treatment groups will receive standard supportive care. Aim is randomise and initiate treatment of 152 patients. For the final analysis, a minimum of 129 evaluable patients will be required.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interferon Beta-1A | Lyophilisate for solution for injection. |
| DRUG | Placebo | Lyophilisate for solution for injection as placebo. |
Timeline
- Start date
- 2017-02-18
- Primary completion
- 2019-09-23
- Completion
- 2019-10-03
- First posted
- 2017-04-19
- Last updated
- 2021-01-14
- Results posted
- 2021-01-14
Locations
9 sites across 3 countries: Estonia, Finland, Lithuania
Source: ClinicalTrials.gov record NCT03119701. Inclusion in this directory is not an endorsement.